Clinical characteristics and outcomes of diffuse large B-cell lymphoma in adolescents and young adults

  • Yasuhiro Suzuki
  • Takahiro Yano
  • Youko Suehiro
  • Hiromi Iwasaki
  • Michihiro Hidaka
  • Maki Otsuka
  • Kazutaka Sunami
  • Nobumasa Inoue
  • Morio Sawamura
  • Takuo Ito
  • Hiroatsu Iida
  • Hirokazu Nagai
Original Article
  • 62 Downloads

Abstract

Clinical information regarding non-Hodgkin lymphoma (NHL) in adolescents and young adults (AYA) is lacking. We retrospectively analyzed 1426 consecutively registered patients with newly diagnosed NHL. Of 798 DLBCL patients, 42 (5.3%) were identified as AYA (16–39 years). The characteristics of AYA DLBCL patients showed no significant differences compared to older adult DLBCL patients (age ≥ 40 years). Progression-free survival (PFS) and overall survival (OS) in AYA were similar to those in patients aged 40–60 years. However, in older adult groups, PFS and OS were significantly different according to the age group (40–60, 61–79, and ≥ 80 years). In univariate analysis in AYA, performance status, clinical stage, International Prognostic Index (IPI), and age-adjusted IPI significantly affected both PFS and OS. In multivariate analysis, only clinical stage was identified as an independent predictor among AYA. In conclusion, disease characteristics and outcomes of DLBCL in AYA were nearly the same as those in older adults.

Keywords

Non-Hodgkin lymphoma Diffuse large B-cell lymphoma Adolescents Young adults Clinical practice 

Notes

Acknowledgements

This work was supported by a Grant-in-Aid for Clinical Research from the National Hospital Organization. We thank all the participating centers and collaborators of Clinical Hematology Group of National Hospital Organization (CHG-NHO); NHO Hokkaido Medical center, NHO Mito Medical center, NHO Matsumoto Medical center, NHO Kanazawa Medical center, NHO Himeji Medical center, NHO Minami-Okayama Medical center, NHO Hiroshima-Nishi Medical center, and NHO Nagasaki Medical center, for the registration of patients.

Author contributions

HN designed the research; TY, YoS, HIw, MH, MO, KS, NI, MS, TI, and HIi provided the data and contributed to patient care; Ya.S. and HN analyzed and interpreted the data and wrote the manuscript; and all the authors reviewed and revised the manuscript.

Compliance with ethical standards

Conflict-of-interest

Hirokazu Nagai has received research funding from Janssen Pharmaceutical K. K., Mundipharma K.K., Celgene Corporation, Bayer Yakuhin Ltd., Abbvie G.K., Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., and Esai Co., Ltd., and honoraria from Chugai Pharmaceutical Co., Ltd., Mundipharma K.K., Esai Co., Ltd., Sanofi K.K., and Janssen Pharmaceutical K. K. Kazutaka Sunami has received research funding from MSD K. K., Celgene Corporation, and honoraria from Celgene Corporation, Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb. Morio Sawamura has received honoraria from Ono Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Co., Ltd.

Supplementary material

12185_2018_2449_MOESM1_ESM.eps (670 kb)
Supplementary material 1 (EPS 669 kb) Supplemental Fig. 1. Progression-free survival and overall survival of AYA DLBCL patients, comparing the rituximab-containing regimen (rituximab group) with the non-rituximab-containing regimen (non-rituximab group). Kaplan–Meier analysis of progression-free survival (PFS) (a) and overall survival (OS) (b) of AYA DLBCL patients, comparing the rituximab-containing regimen (rituximab group) with the non-rituximab-containing regimen (non-rituximab group) is shown. In this study, the administration of rituximab did not significantly affect PFS and OS (PFS: p = 0.2837, OS: p = 0.4337)
12185_2018_2449_MOESM2_ESM.eps (868 kb)
Supplementary material 2 (EPS 868 kb) Supplemental Fig. 2. Progression-free survival and overall survival in all DLBCL patients, comparing the rituximab-containing regimen (rituximab group) with the non-rituximab-containing regimen (non-rituximab group). Kaplan–Meier analysis of progression-free survival (PFS) (a) and overall survival (OS) (b) in all DLBCL patients showed that the administration of rituximab significantly improved PFS and OS (both P < 0.0001)

References

  1. 1.
    Wood WA, Lee SJ. Malignant hematologic diseases in adolescents and young adults. Blood. 2011;117:5803–15.CrossRefPubMedGoogle Scholar
  2. 2.
    Trama A, Botta L, Foschi R, Ferrari A, Stiller C, Desandes E, et al. Survival of European adolescents and young adults diagnosed with cancer in 2000–07: population-based data from EUROCARE-5. Lancet Oncol. 2016;17:896–906.CrossRefPubMedGoogle Scholar
  3. 3.
    Wolach O, Ram R. Adolescents and young adults with non-Hodgkin’s lymphoma: slipping between the cracks. Acta Haematol. 2014;132:279–91.CrossRefPubMedGoogle Scholar
  4. 4.
    Bleyer WA, O’Leary M, Barr R, Ries LAG. Cancer epidemiology in older adolescents and young adults 15–29 years of age, including SEER incidence and survival, 1975–2000. Bethesda: National Cancer Institute, NIH Pub. No. 06-5767; 2006.Google Scholar
  5. 5.
    Hochberg J, Waxman IM, Kelly KM, Morris E, Cairo MS. Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science. Br J Haematol. 2009;144:24–40.CrossRefPubMedGoogle Scholar
  6. 6.
    Jaglowski SM, Linden E, Termuhlen AM, Flynn JM. Lymphoma in adolescents and young adults. Semin Oncol. 2009;36:381–418.CrossRefPubMedGoogle Scholar
  7. 7.
    Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006;107:265–76.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Shenoy PJ, Malik N, Nooka A, Sinha R, Ward KC, Brawley OW, et al. Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer. 2011;117:2530–40.CrossRefPubMedGoogle Scholar
  9. 9.
    Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.Google Scholar
  10. 10.
    Jaffe ES, Harris NL, Stein H, Isaacson PG. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood. 2008;112:4384–99.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.CrossRefPubMedGoogle Scholar
  12. 12.
    Coso D, Garciaz S, Esterni B, Broussais-Guillaumot F, Ivanov V, Aurran-Schleinitz T, et al. Large B-cell lymphomas in adolescents and young adults in comparison to adult patients: a matched-control analysis in 55 patients. Leuk Lymphoma. 2014;55:1849–53.CrossRefPubMedGoogle Scholar
  13. 13.
    Klapper W, Kreuz M, Kohler CW, Burkhardt B, Szczepanowski M, Salaverria I, et al. Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. Blood. 2012;119:1882–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837–42.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329:987–94CrossRefGoogle Scholar
  16. 16.
    Stock W, La M, Sanford B, Bloomfield CD, Vardiman JW, Gaynon P, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children’s Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008;112:1646–54.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Hayakawa F, Sakura T, Yujiri T, Kondo E, Fujimaki K, Sasaki O, et al. Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group. Blood Cancer J. 2014;4:e252.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–82.CrossRefPubMedGoogle Scholar
  19. 19.
    Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30:3452–9.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30:3460–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–11.CrossRefPubMedGoogle Scholar
  22. 22.
    Johnson A, Morosini D, Vergilio JA, Yelensky R, Rosenzweig M, Khaira D, et al. Unique genomic features in adolescent and young adult, as compared to older adult, non-Hodgkin lymphoma and potential therapeutic targets. Br J Haematol. 2017;178:640–2.CrossRefPubMedGoogle Scholar
  23. 23.
    Oschlies I, Klapper W, Zimmermann M, Krams M, Wacker HH, Burkhardt B, et al. Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin–Frankfurt–Munster) Multicenter Trial. Blood. 2006;107:4047–52.CrossRefPubMedGoogle Scholar
  24. 24.
    Miles RR, Raphael M, McCarthy K, Wotherspoon A, Lones MA, Terrier-Lacombe MJ, et al. Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: report of the French–American–British (FAB) International Study Group. Pediatr Blood Cancer. 2008;51:369–74.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2018

Authors and Affiliations

  • Yasuhiro Suzuki
    • 1
    • 12
  • Takahiro Yano
    • 2
  • Youko Suehiro
    • 3
  • Hiromi Iwasaki
    • 4
  • Michihiro Hidaka
    • 5
  • Maki Otsuka
    • 6
  • Kazutaka Sunami
    • 7
  • Nobumasa Inoue
    • 8
  • Morio Sawamura
    • 9
  • Takuo Ito
    • 10
  • Hiroatsu Iida
    • 1
  • Hirokazu Nagai
    • 1
    • 11
  1. 1.Department of HematologyNational Hospital Organization Nagoya Medical CenterNagoyaJapan
  2. 2.Department of HematologyNational Hospital Organization Tokyo Medical CenterTokyoJapan
  3. 3.Department of HematologyNational Hospital Organization Kyushu Cancer CenterFukuokaJapan
  4. 4.Department of HematologyNational Hospital Organization Kyushu Medical CenterFukuokaJapan
  5. 5.Department of HematologyNational Hospital Organization Kumamoto Medical CenterKumamotoJapan
  6. 6.Department of HematologyNational Hospital Organization Kagoshima Medical CenterKagoshimaJapan
  7. 7.Department of HematologyNational Hospital Organization Okayama Medical CenterOkayamaJapan
  8. 8.Department of HematologyNational Hospital Organization Osaka Medical CenterOsakaJapan
  9. 9.Department of HematologyNational Hospital Organization Shibukawa Medical CenterShibukawaJapan
  10. 10.Department of HematologyNational Hospital Organization Kure Medical CenterKureJapan
  11. 11.Clinical Research CenterNational Hospital Organization Nagoya Medical CenterNagoyaJapan
  12. 12.Department of HematologyGifu Prefectural Tajimi HospitalTajimiJapan

Personalised recommendations